Literature DB >> 11801764

Resection of hepatic and pulmonary metastases in patients with colorectal cancer.

A Hamy1, O Baron, J Bennouna, J C Roussel, J Paineau, J Y Douillard.   

Abstract

The resection of liver and lung metastases is now regarded as valid therapy, although the surgical procedure of both metastatic sites has not been clearly defined. Nine consecutive patients who underwent resection of both liver and lung metastases from colorectal cancer (5 Dukes' stage B, 3 C, 1 D) between 1986 and 1999 were studied retrospectively. A total of 19 resections were performed: 8 hepatectomies, 2 liver wedge resections, and 9 lung lobectomies. No operative or hospital deaths occurred, and mean postoperative hospital stay per procedure was 12 days. Mean survival after resection of the primary colorectal tumor was 66.3 (range: 26-96) months. The median interval was 24.2 (range: 2-39) months from resection of the liver metastasis and 30.4 (range: 3-45) months from resection of the lung metastasis. At the last follow-up, 6 patients were still alive, 4 of whom were free of recurrence 59, 69, 74, and 76 months, respectively, after resections. Three patients died with metastases. Aggressive treatment of liver and lung secondaries from colorectal cancer was performed without hospital mortality and acceptable morbidity. Longer survival times warrant the use of this alternative therapy for selected patients. In association with new effective chemotherapies, it will be possible to select patients who will benefit from surgery.

Entities:  

Mesh:

Year:  2001        PMID: 11801764     DOI: 10.1097/00000421-200112000-00016

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  1 in total

1.  Sequential surgical resection of hepatic and pulmonary metastases from colorectal cancer.

Authors:  Stefan Limmer; Elisabeth Oevermann; Claudia Killaitis; Peter Kujath; Martin Hoffmann; Hans-Peter Bruch
Journal:  Langenbecks Arch Surg       Date:  2010-02-18       Impact factor: 3.445

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.